| Authors: |
Moyer TJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA., Kato Y; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Abraham W; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Chang JYH; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Kulp DW; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Watson N; Whitehead Institute of Biomedical Research, Cambridge, MA, USA., Turner HL; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA., Menis S; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA., Abbott RK; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Bhiman JN; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Melo MB; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Simon HA; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Herrera-De la Mata S; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Liang S; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Seumois G; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Agarwal Y; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Li N; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Burton DR; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Ward AB; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA., Schief WR; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Crotty S; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.; Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Irvine DJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA. djirvine@mit.edu.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. djirvine@mit.edu.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.; Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.; Howard Hughes Medical Institute, Chevy Chase, MD, USA. djirvine@mit.edu. |
